Genetic and immunologic features associated with thrombocytopenia progression and poor prognosis in patients with myelofibrosis.

ABSTRACT:

Introduction

Myelofibrosis, which includes primary myelofibrosis (PMF) and secondary myelofibrosis (SMF), can exhibit cytopenic features associated with poor outcomes; however, the underlying mechanisms are unclear. Moreover, characterized by its aggressive nature and limited therapeutic options, myelofibrosis poses a major clinical challenge in hematology. Therefore, in this study, we aimed to identify genetic and immunologic features associated with thrombocytopenia progression and poor prognosis.

Methods

The study involved 226 patients with PMF or SMF, who were categorized into three groups: platelet count ≥ 100 × 10⁹/L (PLT ≥ 100 group; n = 131), progression to thrombocytopenia (PROG group; n = 64), and platelet count < 100 × 10⁹/L (PLT < 100 group;

SUBMITTER: Kim TY 

PROVIDER: S-EPMC11580038 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature